Bahija Jallal, Executive Vice-President of MedImmune, is responsible for biologics research, development and clinical activities. Bahija joined MedImmune as Vice-President, Translational Sciences in 2006. She has guided the MedImmune R&D organisation through unprecedented expansion of its pipeline from 40 drugs to more than 120. Biologics now makes up 50% of AstraZeneca’s pipeline. Bahija has authored more than 70 peer-reviewed publications and holds more than 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science, the Pharmacogenomics Working Group and is a member of the Board of Directors of the Association of Women in Science. Bahija also serves on the Board of Trustees of the Johns Hopkins University in Baltimore, Maryland. Bahija received a master’s degree in Biology from the Universite de Paris VII in France, and her doctorate in Physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

Biologics research, development and clinical activities